How has been the historical performance of Glaxosmi. Pharma?

Answer:The historical performance of Glaxosmi. Pharma shows a consistent growth in net sales and profit over the years, with significant fluctuations in certain metrics.

Breakdown:
Glaxosmi. Pharma's net sales have increased from 3,128.12 Cr in Mar'19 to 3,749.21 Cr in Mar'25, reflecting a steady upward trend. The total operating income followed a similar trajectory, rising from 3,128.12 Cr in Mar'19 to 3,749.21 Cr in Mar'25. Operating profit (PBDIT) also saw growth, climbing from 600.79 Cr in Mar'19 to 1,323.29 Cr in Mar'25, with an operating profit margin that improved from 19.21% to 31.4% during the same period. Profit before tax rose significantly from 682.66 Cr in Mar'19 to 1,259.88 Cr in Mar'25, while profit after tax increased from 445.39 Cr to 927.58 Cr. However, net profit showed fluctuations, peaking at 1,694.72 Cr in Mar'22 before dropping to 927.58 Cr in Mar'25. The company's total assets increased from 3,025.05 Cr in Mar'20 to 3,967.20 Cr in Mar'25, while total liabilities also rose from 3,025.05 Cr to 3,967.20 Cr in the same timeframe. Cash flow from operating activities improved significantly, reaching 1,289.00 Cr in Mar'25 compared to 490.00 Cr in Mar'20, contributing to a closing cash balance of 538.00 Cr in Mar'25, up from 104.00 Cr in Mar'20. Overall, Glaxosmi. Pharma has demonstrated a robust growth trajectory in sales and profitability, despite some variability in net profit and asset levels.